ArticleThe Journal of thoracic and cardiovascular surgery2020
The Pediatric Heart Network Residual Lesion Score Study: Design and objectives.
Article in The Journal of thoracic and cardiovascular surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Predicting Cardiac Magnetic Resonance-Derived Ejection Fraction from Echocardiogram Via Deep Learning Approach in Tetralogy of Fallot.Pediatric cardiology · 2026Article
- Correlation of right ventricular outflow tract residual disease on post-op transesophageal echocardiography and discharge transthoracic echocardiography after tetralogy of fallot repair.The international journal of cardiovascular imaging · 2025Article
- Evaluating Procedural Performance: A Composite Outcome for Atrial Septal Defect and Patent Ductus Arteriosus Closures.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Article
- Collaborating to Improve Outcomes in Congenital Heart Disease: The Pediatric Heart Network Experience.Congenital heart disease · 2025Article
- Days alive and out of hospital for children born with single-ventricle heart disease.Cardiology in the young · 2024Article
- Echocardiographic image collection and evaluation in infants with CHD: lessons learned from the imaging core lab for the Residual Lesion Score study.Cardiology in the young · 2024Article
- Ventriculo-arterial coupling for predicting cardiac index increase in infants after heart surgery.Interdisciplinary cardiovascular and thoracic surgery · 2023Article
- Development of the Residual Lesion Score for congenital heart surgery: the RAND Delphi methodology.Cardiology in the young · 2023Article
- Impact of Neighborhood Socioeconomic Status on Outcomes Following First-Stage Palliation of Single Ventricle Heart Disease.Journal of the American Heart Association · 2023Article
- Characterization of "ICU-30": A Binary Composite Outcome for Neonates With Critical Congenital Heart Disease.Journal of the American Heart Association · 2022Article
- Impact of Major Residual Lesions on Outcomes After Surgery for Congenital Heart Disease.Journal of the American College of Cardiology · 2021Observational
- Registry-based trials: a potential model for cost savings?Cardiology in the young · 2020Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
16 authors.
Funding
Abstract
objectivesThe Residual Lesion Score (RLS) was developed as a novel tool for assessing residual lesions after congenital heart operations based on widely available clinical and echocardiographic characteristics. The RLS ranks postoperative findings as follows: Class 1 (no/trivial residua), Class 2 (minor residua), or Class 3 (major residua or reintervention before discharge for residua). The multicenter prospective RLS study aims to analyze the influence of residual lesions on outcomes in common congenital cardiac operations. We hypothesize that RLS will predict postoperative adverse events, resource utilization, mortality, and reinterventions by 1 year postoperatively.
methodsThe study cohort consisted of infants aged ≤12 months undergoing definitive surgery for complete atrioventricular septal defect, tetralogy of Fallot, dextro-transposition of the great arteries with or without intact ventricular septum, single ventricle (Norwood procedure), and coarctation or interrupted/hypoplastic arch with ventricular septal defect. Children with major congenital or acquired extracardiac anomalies that could independently affect the primary end point, which was number of days alive and out of the hospital within 30 days of surgery (60 days for Norwood procedure), were excluded. Secondary outcomes included ≥1 early major postoperative adverse event; days of intensive care unit and hospital stay, and initial and total ventilator time; mortality/transplant after discharge; unplanned reinterventions after discharge; and cost. All analyses will be performed separately by surgical operation.
conclusionsThis is the first multicenter prospective validation of a tool for surgical outcome assessment and quality improvement specific to congenital heart surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.